Uncategorized

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

by Business Wire • 2022/02/11 • 0 Comments

NEW YORK--(BUSINESS WIRE)--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters.

← New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss

TNF inhibition may be effective in Stevens-Johnson syndrome/toxic epidermal necrolysis →

Post navigation